Articles related to ANTIVIRALS

In a trial of 2,736 participants, nirmatrelvir-ritonavir given as postexposure prophylaxis for 5 or 10 days did not significantly reduce the risk of symptomatic SARS-CoV-2 infection compared to placebo among household contacts of COVID-19 patients.

Immunocompromised individuals are at a 6 to 11 times higher risk of developing herpes zoster compared to the general population, with hematopoietic stem cell transplant recipients facing the highest risk.

Integrating telehealth into opioid treatment programs drastically improves hepatitis C cure rates, particularly among underserved populations, by facilitating seamless access to DAAs and continuous follow-up care.

In a recent phase 2–3 trial, nirmatrelvir–ritonavir did not significantly shorten the time to COVID-19 symptom resolution compared to placebo, yet it demonstrated a trend towards reduced hospitalization and death rates, emphasizing the importance of tailored treatment strategies.

In the battle against recurrent herpes simplex virus infections, chronic suppressive therapy emerges as a pivotal strategy, diminishing both the physical burden of outbreaks and the psychological weight of potential transmission.

In the high-risk patient cohort, the combination of baricitinib and remdesivir not only demonstrated a significant reduction in mortality and progression to invasive mechanical ventilation but also showcased an enhanced recovery trajectory.